Forge is a hybrid gene therapy company advancing an AAV pipeline and providing CDMO manufacturing. Forge’s lead program, FBX-101 is an AAV gene therapy for treatment of patients with Krabbe disease. FBX-101 will be entering clinical trials in 2021
Krabbe disease is a rare, pediatric leukodystrophy affecting about 1 in 100,000 people and is inherited in an autosomal recessive manner.
Forge’s gene therapy FBX-101 aims to treat patients with infantile Krabbe disease. FBX-101 utilizes an adeno-associated viral (AAV) gene therapy infusion after an umbilical cord blood transplant to deliver the GALC gene to cells in both the central and peripheral nervous system.
RESKUE Trial for Patients with Krabbe Disease
With new beginnings comes new hope. As we enter 2021, screening will begin for our Phase 1/2 RESKUE trial – a first-in-human gene therapy clinical trial for patients with Krabbe disease. Learn more about the RESKUE trial here – https://clinicaltrials.gov/ct2/show/NCT04693598?term=NCT04693598